Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    TransCode Therapeutics In...

    NASDAQ: RNAZ · Real-Time Price · USD
    7.28
    -0.02 (-0.27%)
    At close: Jun 17, 2025, 10:32 AM

    TransCode Therapeutics Statistics

    Share Statistics

    TransCode Therapeutics has 833.62K shares outstanding. The number of shares has increased by 0.78% in one year.

    Shares Outstanding

    n/a
    		 833.62K

    Shares Change (YoY)

    n/a
    		 0.78%

    Shares Change (QoQ)

    n/a
    		 0%

    Owned by Institutions (%)

    n/a
    		 0.09%

    Shares Floating

    n/a
    		 833.62K

    Failed to Deliver (FTD) Shares

    n/a
    		 79,593

    FTD / Avg. Volume

    n/a
    		 24.81%

    Short Selling Information

    The latest short interest is 115.43K, so 13.85% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 115.43K

    Short % of Shares Out

    n/a
    		 13.85%

    Short % of Float

    n/a
    		 13.85%

    Short Ratio (days to cover)

    n/a
    		 1.02

    Valuation Ratios

    The PE ratio is -1.4 and the forward PE ratio is -0.76. TransCode Therapeutics's PEG ratio is 0.01.

    PE Ratio

    n/a
    		 -1.4

    Forward PE

    n/a
    		 -0.76

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.2

    PB Ratio

    n/a
    		 -11.66

    P/FCF Ratio

    n/a
    		 -1.76

    PEG Ratio

    n/a
    		 0.01
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for TransCode Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.56, with a Debt / Equity ratio of -0.02.

    Current Ratio

    n/a
    		 2.56

    Quick Ratio

    n/a
    		 2.56

    Debt / Equity

    n/a
    		 -0.02

    Debt / EBITDA

    n/a
    		 n/a

    Debt / FCF

    n/a
    		 n/a

    Interest Coverage

    n/a
    		 -584.07

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-2,393,567.29

    Employee Count

    n/a
    		 7

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -99.01% in the last 52 weeks. The beta is 1.33, so TransCode Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.33

    52-Week Price Change

    n/a
    		 -99.01%

    50-Day Moving Average

    n/a
    		 173.1

    200-Day Moving Average

    n/a
    		 198

    Relative Strength Index (RSI)

    n/a
    		 26.96

    Average Volume (20 Days)

    n/a
    		 320,826

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -15.66M

    Net Income

    n/a
    		 -16.75M

    EBITDA

    n/a
    		 -16.19M

    EBIT

    n/a
    		 -14.57M

    Earnings Per Share (EPS)

    n/a
    		 -47.14
    Full Income Statement

    Balance Sheet

    The company has 5.81M in cash and 38.29K in debt, giving a net cash position of 5.77M.

    Cash & Cash Equivalents

    n/a
    		 5.81M

    Total Debt

    n/a
    		 38.29K

    Net Cash

    n/a
    		 5.77M

    Retained Earnings

    n/a
    		 -63.2M

    Total Assets

    n/a
    		 13.19B

    Working Capital

    n/a
    		 10.53B
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -13.34M and capital expenditures -21.76K, giving a free cash flow of -13.36M.

    Operating Cash Flow

    n/a
    		 -13.34M

    Capital Expenditures

    n/a
    		 -21.76K

    Free Cash Flow

    n/a
    		 -13.36M

    FCF Per Share

    n/a
    		 -37.51
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    RNAZ does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for RNAZ is $280, which is 3762.1% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $280

    Price Target Difference

    n/a
    		 3762.1%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 1
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on May 15, 2025. It was a backward split with a ratio of 1:28.

    Last Split Date

    n/a
    		 May 15, 2025

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:28

    Scores

    Altman Z-Score

    n/a
    		 -7.03

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist